Learn about the patent cliff and how Novartis’ heart failure drug Vymada (Entresto®) will expire its patent protection in 2023. Find out more about secondary patents that can extend market exclusivity of Entresto® until 2033.
Read more about Profiting from the Patent Cliff: What Drug Manufacturers Need to Know about Secondary Patents